{"id":10737,"date":"2023-05-05T10:30:39","date_gmt":"2023-05-05T07:30:39","guid":{"rendered":"https:\/\/umayanabiotechnology.com\/?p=10737"},"modified":"2023-06-29T19:24:49","modified_gmt":"2023-06-29T16:24:49","slug":"mikro-kadin-girisimci-3uncusu","status":"publish","type":"post","link":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/","title":{"rendered":"Mikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc"},"content":{"rendered":"

[vc_row nav_skin=”light” row_show_on=”wtbx_hide_mobile_landscape,wtbx_hide_mobile_portrait” consent_include=”include”][vc_column css_animation=””][vc_text_element css_animation=””]<\/p>\n

Giri\u015fiminizi kurma fikri nas\u0131l olu\u015ftu? Firman\u0131z\u0131 ne zaman ve nas\u0131l kurdunuz? Bu alana neden y\u00f6neldiniz, bu konudaki motivasyonunuz neydi? K\u0131sa bir \u015fekilde kurulu\u015f \u00f6yk\u00fcn\u00fcz\u00fc payla\u015f\u0131r m\u0131s\u0131n\u0131z?<\/strong><\/p>\n

\"award\"Biyokimya uzman\u0131 olarak Ar-Ge ve ila\u00e7 sekt\u00f6r\u00fc alan\u0131nda 28 y\u0131ll\u0131k bir tecr\u00fcbeye sahibim. Halen Teknopark \u0130stanbul Biocube laboratuvar\u0131nda ara\u015ft\u0131rmalar\u0131ma devam ediyorum. Ara\u015ft\u0131rma deneyimlerimin yan\u0131 s\u0131ra ila\u00e7 sekt\u00f6r\u00fcndeki \u00e7al\u0131\u015fmalar\u0131m; laboratuvarda geli\u015ftirdi\u011fim form\u00fcllerin kullan\u0131ma sunulmas\u0131 i\u00e7in izleyece\u011fim mevzuatlar, \u00fcr\u00fcnlerin finansal analizleri, pazarda konumlanmas\u0131 gibi konularda tecr\u00fcbe kazanmama sebep oldu.<\/p>\n

Kanser tedavisi nedeniyle hastalarda \u00e7ok \u0131zd\u0131rapl\u0131 a\u011f\u0131z ve cilt yaralar\u0131 olu\u015fmaktad\u0131r. Pazarda yara \u00f6nleyici veya iyile\u015ftirici ihtiyac\u0131 oldu\u011funu g\u00f6zlemledi\u011fim bu durum, tedavide de ek maliyetler getiriyor. Halihaz\u0131rda global d\u00fczeyde de bu yaralar\u0131 \u00f6nleyen, iyile\u015ftiren \u00fcr\u00fcn yok. Yapt\u0131\u011f\u0131m\u0131z klinik \u00e7al\u0131\u015fmalarda bu soruna \u00e7\u00f6z\u00fcm buldu\u011fumuzu kan\u0131tlayarak, uluslararas\u0131 kongrelerde \u00e7al\u0131\u015fma sunumunu yapt\u0131k.<\/p>\n

Tahmin edilebilece\u011fi gibi ila\u00e7 geli\u015ftirmek olduk\u00e7a titiz bilimsel \u00e7al\u0131\u015fmalar ve mevzuata uygunluk s\u00fcre\u00e7leri gerektiriyor. \u0130la\u00e7 Ar-Ge \u00e7al\u0131\u015fmas\u0131 yapt\u0131\u011f\u0131m i\u00e7in ba\u015flang\u0131\u00e7ta firma kurmad\u0131k ancak geli\u015ftirdi\u011fim form\u00fcllere dair \u00e7al\u0131\u015fmalar\u0131 tamamlad\u0131ktan ve pazar ihtiyac\u0131n\u0131 g\u00f6rd\u00fckten sonra firmam\u0131z\u0131 kurduk.<\/p>\n

Firmam\u0131z\u0131 her birimiz kendi alan\u0131nda ba\u015far\u0131l\u0131, ara\u015ft\u0131rmay\u0131 yapan ben, pazar \u00e7al\u0131\u015fmalar\u0131n\u0131 yapan G\u00fclbin M\u00fcft\u00fco\u011flu ve klinik \u00e7al\u0131\u015fmalar\u0131 ger\u00e7ekle\u015ftiren Prof. Dr. F\u00fcsun Tokatl\u0131 ile birlikte \u00fc\u00e7 kad\u0131n giri\u015fimci olarak bu y\u0131l\u0131n ba\u015f\u0131nda kurduk.<\/p>\n

Yara tedavisinde kullan\u0131lmak \u00fczere Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) ve Amerikan G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA) taraf\u0131ndan kabul edilen bir re\u00e7inenin molek\u00fcllerini yenilik\u00e7i bir metotla elde etti\u011fim ekstrenin ve ilgili form\u00fcllerin patentini ald\u0131k.<\/p>\n

Halihaz\u0131rda bu ekstre ile geli\u015ftirdi\u011fim iki \u00fcr\u00fcn hastalar\u0131n kullan\u0131m\u0131na ve marka tescili de yap\u0131larak ticarile\u015fmeye haz\u0131r hale geldi.<\/p>\n

\u00dcr\u00fcnlerin bilimsel etkinli\u011finin yan\u0131 s\u0131ra pazar plan\u0131, maliyet analizleri de yap\u0131ld\u0131. Mevzuata uygun iyi \u00fcretim \u015fartlar\u0131nda \u00fcretim yapmak \u00fczere tedarik\u00e7i a\u011f\u0131m\u0131z haz\u0131rland\u0131. \u00dcr\u00fcnlerin bilimsel etkinli\u011fi, pazar plan\u0131 ve maliyet analizleri de yap\u0131l\u0131rken, \u00fcretim i\u00e7in Elit \u0130la\u00e7 firmas\u0131yla anla\u015fma sa\u011fland\u0131.<\/p>\n

D\u00fcnyada a\u011f\u0131z yaralar\u0131 konusundaki pazar b\u00fcy\u00fckl\u00fc\u011f\u00fc 2-3 milyar dolar olarak bildiriliyor. Radyodermatit pazar\u0131 ise 1 milyar dolar olarak ifade ediliyor.
\nBulu\u015fa dair \u00e7al\u0131\u015fmalar\u0131ma 2013 y\u0131l\u0131nda kemoterapi ve radyoterapi g\u00f6ren hastalar\u0131n \u00e7ok \u00e7aresiz oldu\u011funu g\u00f6rd\u00fckten sonra ba\u015flad\u0131m. \u00d6ncelikle Ar-Ge ve form\u00fclasyon laboratuvar \u00e7al\u0131\u015fmalar\u0131, akabinde form\u00fcl\u00fcn testleri, \u00f6nleyici – iyile\u015ftirici etkinli\u011fine dair etik kurul onayl\u0131 ve \u00e7ift k\u00f6r kar\u015f\u0131la\u015ft\u0131rmal\u0131 klinik \u00e7al\u0131\u015fmas\u0131 ile kongre sunumlar\u0131n\u0131n ger\u00e7ekle\u015ftirilmesi, biz \u00fc\u00e7 kad\u0131n taraf\u0131ndan kendi \u00f6z kaynaklar\u0131m\u0131z ve bilgilerimizle ger\u00e7ekle\u015ftirildi.<\/p>\n

Her a\u015famas\u0131n\u0131 titizlikle yapabilmek ve ayn\u0131 zamanda hayat\u0131m\u0131z\u0131 devam ettirmek i\u00e7in \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z i\u015flerle birlikte bu \u00e7al\u0131\u015fmalar\u0131 y\u00fcr\u00fctmek i\u00e7in \u00e7ok yo\u011fun \u00e7al\u0131\u015ft\u0131k. Her a\u015famada gelen hasta yorumlar\u0131 projeye olan inanc\u0131m\u0131z\u0131 art\u0131rd\u0131. 2021 y\u0131l\u0131nda \u00e7al\u0131\u015ft\u0131\u011f\u0131m \u00fcniversiteden ayr\u0131larak tamamen bu projeye yo\u011funla\u015fmak \u00fczere yoluma devam ediyorum. Teknopark \u0130stanbul y\u00f6netimi sayesinde Medical Park Hastaneler Grubu\u2019yla tan\u0131\u015ft\u0131m. \u00dcr\u00fcnlerin etkinli\u011fi onkoloji b\u00f6l\u00fcmlerinde g\u00f6r\u00fcl\u00fcnce Nisan ay\u0131nda \u00fcretim yapmaya karar verdik.<\/p>\n

Faaliyete ba\u015flad\u0131\u011f\u0131n\u0131zda finansa eri\u015fimde s\u0131k\u0131nt\u0131 ya\u015fad\u0131n\u0131z m\u0131? Nas\u0131l desteklerden faydaland\u0131n\u0131z?<\/strong><\/p>\n

\u015eirketimiz Umayana bu y\u0131l\u0131n ba\u015f\u0131nda kuruldu. Bu zaman kadar Ar-Ge, test analiz, pilot \u00fcretim gibi maliyetleri kendimiz kar\u015f\u0131lad\u0131k. Ancak geldi\u011fimiz noktada \u00f6zellikle pazara \u00e7\u0131karken hammadde, \u00fcretim, ambalaj, tasar\u0131m, insan kayna\u011f\u0131 noktalar\u0131nda finansal ihtiya\u00e7lar\u0131m\u0131z artt\u0131. \u015eu anda \u00fcr\u00fcnlerimizi k\u00fc\u00e7\u00fck miktarda \u00fcreterek yurt i\u00e7i ve Avrupa pazar\u0131na vermeye haz\u0131rlan\u0131yoruz.<\/p>\n

Kurulu\u015fundan bug\u00fcne \u015firketiniz nas\u0131l bir geli\u015fim trendi izledi? Ne kadar b\u00fcy\u00fcd\u00fcn\u00fcz, cironuzu hangi a\u015famaya ta\u015f\u0131d\u0131n\u0131z?<\/strong><\/p>\n

Hen\u00fcz bir cirodan bahsedemeyiz ancak k\u00fc\u00e7\u00fck ad\u0131mlarla sa\u011flam y\u00fcr\u00fcmeyi tercih ediyoruz. Medical Park, Medicana ve Liv Hospital Radyo Onkoloji departmanlar\u0131nca \u00fcr\u00fcnlerimiz talep edilmeye ba\u015fland\u0131.<\/p>\n

\u015eirketinizi kurdu\u011funuzda ka\u00e7 ki\u015fi \u00e7al\u0131\u015f\u0131yordu, \u015fu an ka\u00e7 ki\u015fiyi istihdam ediyorsunuz? \u0130stihdam\u0131n\u0131z\u0131 art\u0131rma hedefiniz var m\u0131? Kad\u0131n istihdam oran\u0131n\u0131z nedir?<\/strong><\/p>\n

\u0130lk ad\u0131m\u0131m\u0131z\u0131, klinik \u00e7al\u0131\u015fmam\u0131z\u0131 yapan Prof. Dr. F\u00fcsun Tokatl\u0131 ile att\u0131k. K\u0131sa s\u00fcre\u00e7te marketing y\u00f6neticisi ve lojistik hizmetlerinden sorumlu 2 ki\u015fiyi istihdam edece\u011fiz.<\/p>\n

\u0130hracat yap\u0131yorsan\u0131z, ne zaman ba\u015flad\u0131n\u0131z ve hangi \u00fclkelere ihracat yap\u0131yorsunuz? \u0130hracatta hedefiniz nedir?<\/strong><\/p>\n

Bel\u00e7ika\u2019ya Leuven Hook ve Antwerp hastanelerinde kullan\u0131lmak \u00fczere ihracat yapmaya haz\u0131rlan\u0131yoruz.<\/p>\n

\u0130\u00e7inde bulundu\u011funuz sekt\u00f6r\u00fcn hangi zorluklar\u0131 var? Bu zorluklarla nas\u0131l m\u00fccadele ediyorsunuz?<\/strong><\/p>\n

\u0130la\u00e7 sekt\u00f6r\u00fc hem \u00e7ok hay\u0131rl\u0131 hem de \u00e7ok zorluklar\u0131 olan bir alan. Hammaddeden \u00fcretime kadar her \u015feyin mevzuata uyumlu olmas\u0131 gerekli. Ayr\u0131ca patentli form\u00fcl\u00fcn\u00fcz\u00fc profesyonel \u00fcretmeniz \u015fart. \u00dcretim sonras\u0131 hastaya kadar ula\u015fmas\u0131 s\u00fcrecinin de detayl\u0131 d\u00fc\u015f\u00fcn\u00fclmesi gerekiyor. Bu nedenle ad\u0131m ad\u0131m her a\u015famay\u0131 planlayarak gidiyoruz.<\/p>\n

Elbette bunlar a\u015f\u0131lmayacak konular de\u011fil. \u00c7ok \u00e7al\u0131\u015fmak gerekiyor fakat olmas\u0131 gerekeni yaparak ilerledik. S\u00fcre\u00e7te ad\u0131m ad\u0131m yava\u015f da olsa hep ilerleyerek devam ettik. Finansal zorluklar fedakarl\u0131kta bulunmam\u0131z\u0131 gerektirse de hi\u00e7 vazge\u00e7medik.<\/p>\n

Bug\u00fcne kadar Halkbank\u2019\u0131n farkl\u0131 finansal desteklerinden faydaland\u0131n\u0131z m\u0131?<\/strong><\/p>\n

Halkbank’\u0131n 2017 y\u0131l\u0131ndan bu yana emekli m\u00fc\u015fterisiyim. Bu \u00fcr\u00fcnlerin test masraflar\u0131 i\u00e7in iki kez kredi ald\u0131m. Daima en iyi imkanlar\u0131 sunan Halkbank ve \u00e7al\u0131\u015fanlar\u0131 beni hi\u00e7 geri \u00e7evirmedi. \u00dcreten Kad\u0131nlar Yar\u0131\u015fmas\u0131\u2019na \u00e7ok zor bir alanda etkin oldu\u011funu kan\u0131tlad\u0131\u011f\u0131m\u0131z \u00fcr\u00fcnlerin, \u00f6nce T\u00fcrkiye’de sonra d\u00fcnyada pazara sunulabilmesi i\u00e7in gereken ilk yat\u0131r\u0131m maliyetlerini alabilmek ve Halkbank arac\u0131l\u0131\u011f\u0131yla \u00fcr\u00fcnlerimizi duyurabilmek i\u00e7in kat\u0131ld\u0131m.<\/p>\n

Umayana firmas\u0131n\u0131n ticari hesab\u0131n\u0131 da Halkbank\u2019ta a\u00e7t\u0131\u011f\u0131mda, \u015fube m\u00fcd\u00fcr\u00fc ve uzmanlar\u0131 yar\u0131\u015fmaya girmem i\u00e7in beni cesaretlendirdi. Devlet Bankas\u0131 olan Halkbank’\u0131n g\u00fcc\u00fcne inan\u0131yorum. Halkbank\u2019la firmam\u0131n sadece T\u00fcrkiye’de de\u011fil, globalde de ba\u015far\u0131l\u0131 olaca\u011f\u0131na inanc\u0131m sonsuz. Halen Halkbank ile \u00e7al\u0131\u015fmaktan b\u00fcy\u00fck memnuniyet duyuyorum. Ekibin g\u00fcler y\u00fczl\u00fcl\u00fc\u011f\u00fc ve yard\u0131mc\u0131 yakla\u015f\u0131m\u0131 bence \u00e7ok \u00f6nemli.<\/p>\n

Halkbank \u00dcreten Kad\u0131nlar Yar\u0131\u015fmas\u0131\u2019ndan kazand\u0131\u011f\u0131n\u0131z \u00f6d\u00fcllerin size ve i\u015finize nas\u0131l bir katk\u0131s\u0131 olacak?<\/strong><\/p>\n

Bu \u00f6d\u00fcl tam zaman\u0131nda, \u00fcretim a\u015famas\u0131nda verildi\u011fi i\u00e7in ilk \u00fcretim maliyetlerinde bize katk\u0131 sa\u011flad\u0131.<\/p>\n

Gelecek hedeflerinizden bahsedebilir misiniz?<\/strong><\/p>\n

Patentli molek\u00fcllerimiz, kozmetikten ilaca dek pek \u00e7ok alanda kullan\u0131labilir. Hedefimiz \u00f6ncelikle \u00fclkemizde \u00fcretim yaparak d\u00fcnya pazarlar\u0131na girmek. Var olan iki \u00fcr\u00fcn\u00fcm\u00fcz\u00fcn her t\u00fcrl\u00fc alt yap\u0131s\u0131 haz\u0131r. Bu nedenle bir sat\u0131\u015f pazarlama firmas\u0131 ile anla\u015fma yaparak t\u00fcm d\u00fcnyaya yay\u0131lmas\u0131n\u0131 hedefliyoruz. \u015eu anda ilgili g\u00f6r\u00fc\u015fmelerimiz ba\u015flad\u0131. Hedefimiz, sistemi do\u011fru kurarak da\u011f\u0131t\u0131mla birlikte \u00fcretimi de planlayarak ilerlemek.<\/p>\n

[\/vc_text_element][\/vc_column][\/vc_row][vc_row nav_skin=”light” row_show_on=”wtbx_hide_on_normal_screen,wtbx_hide_tablet_landscape,wtbx_hide_tablet_portrait” consent_include=”include”][vc_column css_animation=””][vc_text_element css_animation=””]<\/p>\n

Giri\u015fiminizi kurma fikri nas\u0131l olu\u015ftu? Firman\u0131z\u0131 ne zaman ve nas\u0131l kurdunuz? Bu alana neden y\u00f6neldiniz, bu konudaki motivasyonunuz neydi? K\u0131sa bir \u015fekilde kurulu\u015f \u00f6yk\u00fcn\u00fcz\u00fc payla\u015f\u0131r m\u0131s\u0131n\u0131z?<\/strong><\/p>\n

Biyokimya uzman\u0131 olarak Ar-Ge ve ila\u00e7 sekt\u00f6r\u00fc alan\u0131nda 28 y\u0131ll\u0131k bir tecr\u00fcbeye sahibim. Halen Teknopark \u0130stanbul Biocube laboratuvar\u0131nda ara\u015ft\u0131rmalar\u0131ma devam ediyorum. Ara\u015ft\u0131rma deneyimlerimin yan\u0131 s\u0131ra ila\u00e7 sekt\u00f6r\u00fcndeki \u00e7al\u0131\u015fmalar\u0131m; laboratuvarda geli\u015ftirdi\u011fim form\u00fcllerin kullan\u0131ma sunulmas\u0131 i\u00e7in izleyece\u011fim mevzuatlar, \u00fcr\u00fcnlerin finansal analizleri, pazarda konumlanmas\u0131 gibi konularda tecr\u00fcbe kazanmama sebep oldu.<\/p>\n

Kanser tedavisi nedeniyle hastalarda \u00e7ok \u0131zd\u0131rapl\u0131 a\u011f\u0131z ve cilt yaralar\u0131 olu\u015fmaktad\u0131r. Pazarda yara \u00f6nleyici veya iyile\u015ftirici ihtiyac\u0131 oldu\u011funu g\u00f6zlemledi\u011fim bu durum, tedavide de ek maliyetler getiriyor. Halihaz\u0131rda global d\u00fczeyde de bu yaralar\u0131 \u00f6nleyen, iyile\u015ftiren \u00fcr\u00fcn yok. Yapt\u0131\u011f\u0131m\u0131z klinik \u00e7al\u0131\u015fmalarda bu soruna \u00e7\u00f6z\u00fcm buldu\u011fumuzu kan\u0131tlayarak, uluslararas\u0131 kongrelerde \u00e7al\u0131\u015fma sunumunu yapt\u0131k.<\/p>\n

Tahmin edilebilece\u011fi gibi ila\u00e7 geli\u015ftirmek olduk\u00e7a titiz bilimsel \u00e7al\u0131\u015fmalar ve mevzuata uygunluk s\u00fcre\u00e7leri gerektiriyor. \u0130la\u00e7 Ar-Ge \u00e7al\u0131\u015fmas\u0131 yapt\u0131\u011f\u0131m i\u00e7in ba\u015flang\u0131\u00e7ta firma kurmad\u0131k ancak geli\u015ftirdi\u011fim form\u00fcllere dair \u00e7al\u0131\u015fmalar\u0131 tamamlad\u0131ktan ve pazar ihtiyac\u0131n\u0131 g\u00f6rd\u00fckten sonra firmam\u0131z\u0131 kurduk.<\/p>\n

\"award\"<\/p>\n

Firmam\u0131z\u0131 her birimiz kendi alan\u0131nda ba\u015far\u0131l\u0131, ara\u015ft\u0131rmay\u0131 yapan ben, pazar \u00e7al\u0131\u015fmalar\u0131n\u0131 yapan G\u00fclbin M\u00fcft\u00fco\u011flu ve klinik \u00e7al\u0131\u015fmalar\u0131 ger\u00e7ekle\u015ftiren Prof. Dr. F\u00fcsun Tokatl\u0131 ile birlikte \u00fc\u00e7 kad\u0131n giri\u015fimci olarak bu y\u0131l\u0131n ba\u015f\u0131nda kurduk.<\/p>\n

Yara tedavisinde kullan\u0131lmak \u00fczere Avrupa \u0130la\u00e7 Ajans\u0131 (EMA) ve Amerikan G\u0131da ve \u0130la\u00e7 \u0130daresi (FDA) taraf\u0131ndan kabul edilen bir re\u00e7inenin molek\u00fcllerini yenilik\u00e7i bir metotla elde etti\u011fim ekstrenin ve ilgili form\u00fcllerin patentini ald\u0131k.<\/p>\n

Halihaz\u0131rda bu ekstre ile geli\u015ftirdi\u011fim iki \u00fcr\u00fcn hastalar\u0131n kullan\u0131m\u0131na ve marka tescili de yap\u0131larak ticarile\u015fmeye haz\u0131r hale geldi.<\/p>\n

\u00dcr\u00fcnlerin bilimsel etkinli\u011finin yan\u0131 s\u0131ra pazar plan\u0131, maliyet analizleri de yap\u0131ld\u0131. Mevzuata uygun iyi \u00fcretim \u015fartlar\u0131nda \u00fcretim yapmak \u00fczere tedarik\u00e7i a\u011f\u0131m\u0131z haz\u0131rland\u0131. \u00dcr\u00fcnlerin bilimsel etkinli\u011fi, pazar plan\u0131 ve maliyet analizleri de yap\u0131l\u0131rken, \u00fcretim i\u00e7in Elit \u0130la\u00e7 firmas\u0131yla anla\u015fma sa\u011fland\u0131.<\/p>\n

D\u00fcnyada a\u011f\u0131z yaralar\u0131 konusundaki pazar b\u00fcy\u00fckl\u00fc\u011f\u00fc 2-3 milyar dolar olarak bildiriliyor. Radyodermatit pazar\u0131 ise 1 milyar dolar olarak ifade ediliyor.
\nBulu\u015fa dair \u00e7al\u0131\u015fmalar\u0131ma 2013 y\u0131l\u0131nda kemoterapi ve radyoterapi g\u00f6ren hastalar\u0131n \u00e7ok \u00e7aresiz oldu\u011funu g\u00f6rd\u00fckten sonra ba\u015flad\u0131m. \u00d6ncelikle Ar-Ge ve form\u00fclasyon laboratuvar \u00e7al\u0131\u015fmalar\u0131, akabinde form\u00fcl\u00fcn testleri, \u00f6nleyici – iyile\u015ftirici etkinli\u011fine dair etik kurul onayl\u0131 ve \u00e7ift k\u00f6r kar\u015f\u0131la\u015ft\u0131rmal\u0131 klinik \u00e7al\u0131\u015fmas\u0131 ile kongre sunumlar\u0131n\u0131n ger\u00e7ekle\u015ftirilmesi, biz \u00fc\u00e7 kad\u0131n taraf\u0131ndan kendi \u00f6z kaynaklar\u0131m\u0131z ve bilgilerimizle ger\u00e7ekle\u015ftirildi.<\/p>\n

Her a\u015famas\u0131n\u0131 titizlikle yapabilmek ve ayn\u0131 zamanda hayat\u0131m\u0131z\u0131 devam ettirmek i\u00e7in \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z i\u015flerle birlikte bu \u00e7al\u0131\u015fmalar\u0131 y\u00fcr\u00fctmek i\u00e7in \u00e7ok yo\u011fun \u00e7al\u0131\u015ft\u0131k. Her a\u015famada gelen hasta yorumlar\u0131 projeye olan inanc\u0131m\u0131z\u0131 art\u0131rd\u0131. 2021 y\u0131l\u0131nda \u00e7al\u0131\u015ft\u0131\u011f\u0131m \u00fcniversiteden ayr\u0131larak tamamen bu projeye yo\u011funla\u015fmak \u00fczere yoluma devam ediyorum. Teknopark \u0130stanbul y\u00f6netimi sayesinde Medical Park Hastaneler Grubu\u2019yla tan\u0131\u015ft\u0131m. \u00dcr\u00fcnlerin etkinli\u011fi onkoloji b\u00f6l\u00fcmlerinde g\u00f6r\u00fcl\u00fcnce Nisan ay\u0131nda \u00fcretim yapmaya karar verdik.<\/p>\n

Faaliyete ba\u015flad\u0131\u011f\u0131n\u0131zda finansa eri\u015fimde s\u0131k\u0131nt\u0131 ya\u015fad\u0131n\u0131z m\u0131? Nas\u0131l desteklerden faydaland\u0131n\u0131z?<\/strong><\/p>\n

\u015eirketimiz Umayana bu y\u0131l\u0131n ba\u015f\u0131nda kuruldu. Bu zaman kadar Ar-Ge, test analiz, pilot \u00fcretim gibi maliyetleri kendimiz kar\u015f\u0131lad\u0131k. Ancak geldi\u011fimiz noktada \u00f6zellikle pazara \u00e7\u0131karken hammadde, \u00fcretim, ambalaj, tasar\u0131m, insan kayna\u011f\u0131 noktalar\u0131nda finansal ihtiya\u00e7lar\u0131m\u0131z artt\u0131. \u015eu anda \u00fcr\u00fcnlerimizi k\u00fc\u00e7\u00fck miktarda \u00fcreterek yurt i\u00e7i ve Avrupa pazar\u0131na vermeye haz\u0131rlan\u0131yoruz.<\/p>\n

Kurulu\u015fundan bug\u00fcne \u015firketiniz nas\u0131l bir geli\u015fim trendi izledi? Ne kadar b\u00fcy\u00fcd\u00fcn\u00fcz, cironuzu hangi a\u015famaya ta\u015f\u0131d\u0131n\u0131z?<\/strong><\/p>\n

Hen\u00fcz bir cirodan bahsedemeyiz ancak k\u00fc\u00e7\u00fck ad\u0131mlarla sa\u011flam y\u00fcr\u00fcmeyi tercih ediyoruz. Medical Park, Medicana ve Liv Hospital Radyo Onkoloji departmanlar\u0131nca \u00fcr\u00fcnlerimiz talep edilmeye ba\u015fland\u0131.<\/p>\n

\u015eirketinizi kurdu\u011funuzda ka\u00e7 ki\u015fi \u00e7al\u0131\u015f\u0131yordu, \u015fu an ka\u00e7 ki\u015fiyi istihdam ediyorsunuz? \u0130stihdam\u0131n\u0131z\u0131 art\u0131rma hedefiniz var m\u0131? Kad\u0131n istihdam oran\u0131n\u0131z nedir?<\/strong><\/p>\n

\u0130lk ad\u0131m\u0131m\u0131z\u0131, klinik \u00e7al\u0131\u015fmam\u0131z\u0131 yapan Prof. Dr. F\u00fcsun Tokatl\u0131 ile att\u0131k. K\u0131sa s\u00fcre\u00e7te marketing y\u00f6neticisi ve lojistik hizmetlerinden sorumlu 2 ki\u015fiyi istihdam edece\u011fiz.<\/p>\n

\u0130hracat yap\u0131yorsan\u0131z, ne zaman ba\u015flad\u0131n\u0131z ve hangi \u00fclkelere ihracat yap\u0131yorsunuz? \u0130hracatta hedefiniz nedir?<\/strong><\/p>\n

Bel\u00e7ika\u2019ya Leuven Hook ve Antwerp hastanelerinde kullan\u0131lmak \u00fczere ihracat yapmaya haz\u0131rlan\u0131yoruz.<\/p>\n

\u0130\u00e7inde bulundu\u011funuz sekt\u00f6r\u00fcn hangi zorluklar\u0131 var? Bu zorluklarla nas\u0131l m\u00fccadele ediyorsunuz?<\/strong><\/p>\n

\u0130la\u00e7 sekt\u00f6r\u00fc hem \u00e7ok hay\u0131rl\u0131 hem de \u00e7ok zorluklar\u0131 olan bir alan. Hammaddeden \u00fcretime kadar her \u015feyin mevzuata uyumlu olmas\u0131 gerekli. Ayr\u0131ca patentli form\u00fcl\u00fcn\u00fcz\u00fc profesyonel \u00fcretmeniz \u015fart. \u00dcretim sonras\u0131 hastaya kadar ula\u015fmas\u0131 s\u00fcrecinin de detayl\u0131 d\u00fc\u015f\u00fcn\u00fclmesi gerekiyor. Bu nedenle ad\u0131m ad\u0131m her a\u015famay\u0131 planlayarak gidiyoruz.<\/p>\n

Elbette bunlar a\u015f\u0131lmayacak konular de\u011fil. \u00c7ok \u00e7al\u0131\u015fmak gerekiyor fakat olmas\u0131 gerekeni yaparak ilerledik. S\u00fcre\u00e7te ad\u0131m ad\u0131m yava\u015f da olsa hep ilerleyerek devam ettik. Finansal zorluklar fedakarl\u0131kta bulunmam\u0131z\u0131 gerektirse de hi\u00e7 vazge\u00e7medik.<\/p>\n

Bug\u00fcne kadar Halkbank\u2019\u0131n farkl\u0131 finansal desteklerinden faydaland\u0131n\u0131z m\u0131?<\/strong><\/p>\n

Halkbank’\u0131n 2017 y\u0131l\u0131ndan bu yana emekli m\u00fc\u015fterisiyim. Bu \u00fcr\u00fcnlerin test masraflar\u0131 i\u00e7in iki kez kredi ald\u0131m. Daima en iyi imkanlar\u0131 sunan Halkbank ve \u00e7al\u0131\u015fanlar\u0131 beni hi\u00e7 geri \u00e7evirmedi. \u00dcreten Kad\u0131nlar Yar\u0131\u015fmas\u0131\u2019na \u00e7ok zor bir alanda etkin oldu\u011funu kan\u0131tlad\u0131\u011f\u0131m\u0131z \u00fcr\u00fcnlerin, \u00f6nce T\u00fcrkiye’de sonra d\u00fcnyada pazara sunulabilmesi i\u00e7in gereken ilk yat\u0131r\u0131m maliyetlerini alabilmek ve Halkbank arac\u0131l\u0131\u011f\u0131yla \u00fcr\u00fcnlerimizi duyurabilmek i\u00e7in kat\u0131ld\u0131m.<\/p>\n

Umayana firmas\u0131n\u0131n ticari hesab\u0131n\u0131 da Halkbank\u2019ta a\u00e7t\u0131\u011f\u0131mda, \u015fube m\u00fcd\u00fcr\u00fc ve uzmanlar\u0131 yar\u0131\u015fmaya girmem i\u00e7in beni cesaretlendirdi. Devlet Bankas\u0131 olan Halkbank’\u0131n g\u00fcc\u00fcne inan\u0131yorum. Halkbank\u2019la firmam\u0131n sadece T\u00fcrkiye’de de\u011fil, globalde de ba\u015far\u0131l\u0131 olaca\u011f\u0131na inanc\u0131m sonsuz. Halen Halkbank ile \u00e7al\u0131\u015fmaktan b\u00fcy\u00fck memnuniyet duyuyorum. Ekibin g\u00fcler y\u00fczl\u00fcl\u00fc\u011f\u00fc ve yard\u0131mc\u0131 yakla\u015f\u0131m\u0131 bence \u00e7ok \u00f6nemli.<\/p>\n

Halkbank \u00dcreten Kad\u0131nlar Yar\u0131\u015fmas\u0131\u2019ndan kazand\u0131\u011f\u0131n\u0131z \u00f6d\u00fcllerin size ve i\u015finize nas\u0131l bir katk\u0131s\u0131 olacak?<\/strong><\/p>\n

Bu \u00f6d\u00fcl tam zaman\u0131nda, \u00fcretim a\u015famas\u0131nda verildi\u011fi i\u00e7in ilk \u00fcretim maliyetlerinde bize katk\u0131 sa\u011flad\u0131.<\/p>\n

Gelecek hedeflerinizden bahsedebilir misiniz?<\/strong><\/p>\n

Patentli molek\u00fcllerimiz, kozmetikten ilaca dek pek \u00e7ok alanda kullan\u0131labilir. Hedefimiz \u00f6ncelikle \u00fclkemizde \u00fcretim yaparak d\u00fcnya pazarlar\u0131na girmek. Var olan iki \u00fcr\u00fcn\u00fcm\u00fcz\u00fcn her t\u00fcrl\u00fc alt yap\u0131s\u0131 haz\u0131r. Bu nedenle bir sat\u0131\u015f pazarlama firmas\u0131 ile anla\u015fma yaparak t\u00fcm d\u00fcnyaya yay\u0131lmas\u0131n\u0131 hedefliyoruz. \u015eu anda ilgili g\u00f6r\u00fc\u015fmelerimiz ba\u015flad\u0131. Hedefimiz, sistemi do\u011fru kurarak da\u011f\u0131t\u0131mla birlikte \u00fcretimi de planlayarak ilerlemek.<\/p>\n

[\/vc_text_element][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row nav_skin=”light” row_show_on=”wtbx_hide_mobile_landscape,wtbx_hide_mobile_portrait” consent_include=”include”][vc_column css_animation=””][vc_text_element css_animation=””] Giri\u015fiminizi kurma fikri nas\u0131l olu\u015ftu? Firman\u0131z\u0131 ne zaman ve nas\u0131l kurdunuz? Bu alana neden y\u00f6neldiniz, bu konudaki motivasyonunuz neydi? K\u0131sa bir \u015fekilde kurulu\u015f \u00f6yk\u00fcn\u00fcz\u00fc payla\u015f\u0131r m\u0131s\u0131n\u0131z? Biyokimya uzman\u0131 olarak Ar-Ge ve ila\u00e7 sekt\u00f6r\u00fc alan\u0131nda 28 y\u0131ll\u0131k bir tecr\u00fcbeye sahibim. Halen Teknopark \u0130stanbul Biocube laboratuvar\u0131nda ara\u015ft\u0131rmalar\u0131ma devam ediyorum. Ara\u015ft\u0131rma deneyimlerimin yan\u0131 s\u0131ra ila\u00e7 sekt\u00f6r\u00fcndeki \u00e7al\u0131\u015fmalar\u0131m; laboratuvarda geli\u015ftirdi\u011fim form\u00fcllerin kullan\u0131ma sunulmas\u0131 i\u00e7in izleyece\u011fim mevzuatlar, \u00fcr\u00fcnlerin finansal analizleri, pazarda konumlanmas\u0131 gibi konularda […]<\/p>\n","protected":false},"author":2,"featured_media":10883,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"footnotes":""},"categories":[92],"tags":[119],"class_list":["post-10737","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-genel","tag-girisimci","post_format-post-format-image"],"yoast_head":"\nMikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc - Umayana Biotechnology\u00ae<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Murnia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/\",\"url\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/\",\"name\":\"Mikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc - Umayana Biotechnology\u00ae\",\"isPartOf\":{\"@id\":\"https:\/\/umayanabiotechnology.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/umayanabiotechnology.com\/wp-content\/uploads\/2023\/05\/photo.jpg\",\"datePublished\":\"2023-05-05T07:30:39+00:00\",\"dateModified\":\"2023-06-29T16:24:49+00:00\",\"author\":{\"@id\":\"https:\/\/umayanabiotechnology.com\/#\/schema\/person\/98f0807799c3220aa33198af103adee0\"},\"breadcrumb\":{\"@id\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#primaryimage\",\"url\":\"https:\/\/umayanabiotechnology.com\/wp-content\/uploads\/2023\/05\/photo.jpg\",\"contentUrl\":\"https:\/\/umayanabiotechnology.com\/wp-content\/uploads\/2023\/05\/photo.jpg\",\"width\":1900,\"height\":1180},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/umayanabiotechnology.com\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/umayanabiotechnology.com\/#website\",\"url\":\"https:\/\/umayanabiotechnology.com\/\",\"name\":\"Umayana Biotechnology\u00ae\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/umayanabiotechnology.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/umayanabiotechnology.com\/#\/schema\/person\/98f0807799c3220aa33198af103adee0\",\"name\":\"Murnia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/umayanabiotechnology.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/47fbc94a877f897312be9fef8698cbf7aa679041a1e646e0d1cc7b875fa334fa?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/47fbc94a877f897312be9fef8698cbf7aa679041a1e646e0d1cc7b875fa334fa?s=96&d=mm&r=g\",\"caption\":\"Murnia\"},\"sameAs\":[\"https:\/\/umayanabiotechnology.com\"],\"url\":\"https:\/\/umayanabiotechnology.com\/tr\/author\/murnia\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc - Umayana Biotechnology\u00ae","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/","twitter_misc":{"Yazan:":"Murnia","Tahmini okuma s\u00fcresi":"13 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/","url":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/","name":"Mikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc - Umayana Biotechnology\u00ae","isPartOf":{"@id":"https:\/\/umayanabiotechnology.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#primaryimage"},"image":{"@id":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#primaryimage"},"thumbnailUrl":"https:\/\/umayanabiotechnology.com\/wp-content\/uploads\/2023\/05\/photo.jpg","datePublished":"2023-05-05T07:30:39+00:00","dateModified":"2023-06-29T16:24:49+00:00","author":{"@id":"https:\/\/umayanabiotechnology.com\/#\/schema\/person\/98f0807799c3220aa33198af103adee0"},"breadcrumb":{"@id":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#primaryimage","url":"https:\/\/umayanabiotechnology.com\/wp-content\/uploads\/2023\/05\/photo.jpg","contentUrl":"https:\/\/umayanabiotechnology.com\/wp-content\/uploads\/2023\/05\/photo.jpg","width":1900,"height":1180},{"@type":"BreadcrumbList","@id":"https:\/\/umayanabiotechnology.com\/tr\/mikro-kadin-girisimci-3uncusu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/umayanabiotechnology.com\/tr\/"},{"@type":"ListItem","position":2,"name":"Mikro Kad\u0131n Giri\u015fimci 3\u2019\u00fcnc\u00fcs\u00fc"}]},{"@type":"WebSite","@id":"https:\/\/umayanabiotechnology.com\/#website","url":"https:\/\/umayanabiotechnology.com\/","name":"Umayana Biotechnology\u00ae","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/umayanabiotechnology.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/umayanabiotechnology.com\/#\/schema\/person\/98f0807799c3220aa33198af103adee0","name":"Murnia","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/umayanabiotechnology.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/47fbc94a877f897312be9fef8698cbf7aa679041a1e646e0d1cc7b875fa334fa?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/47fbc94a877f897312be9fef8698cbf7aa679041a1e646e0d1cc7b875fa334fa?s=96&d=mm&r=g","caption":"Murnia"},"sameAs":["https:\/\/umayanabiotechnology.com"],"url":"https:\/\/umayanabiotechnology.com\/tr\/author\/murnia\/"}]}},"_links":{"self":[{"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/posts\/10737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/comments?post=10737"}],"version-history":[{"count":6,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/posts\/10737\/revisions"}],"predecessor-version":[{"id":10747,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/posts\/10737\/revisions\/10747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/media\/10883"}],"wp:attachment":[{"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/media?parent=10737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/categories?post=10737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/umayanabiotechnology.com\/tr\/wp-json\/wp\/v2\/tags?post=10737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}